Recurrent unilateral dactylitis as an unusual presenting manifestation of polycythemia vera: a case report
DOI:
https://doi.org/10.18203/2320-6012.ijrms20263560Keywords:
Polycythemia vera, Dactylitis, Myeloproliferative neoplasm, JAK2 V617F mutation, ThrombosisAbstract
Polycythemia Vera is a chronic myeloproliferative neoplasm characterised by clonal proliferation of erythroid, myeloid, and megakaryocytic cell lines. Typical clinical manifestations include headache, aquagenic pruritus, erythromelalgia, thrombotic events, and splenomegaly. However, atypical presentations may delay diagnosis. We report a rare case of recurrent unilateral dactylitis-like swelling as the presenting manifestation of polycythemia vera in a middle-aged woman. The patient was initially treated for presumed cellulitis because leucocytosis was interpreted in isolation, while the accompanying erythrocytosis and thrombocytosis were overlooked. Recurrent episodes prompted further evaluation, which demonstrated hypercellular bone marrow with panmyelosis and a positive JAK2 V617F mutation, confirming the diagnosis of polycythemia vera”. This case highlights the importance of careful interpretation of complete blood counts, detailed clinical history taking, and maintaining suspicion for haematological disorders in patients presenting with recurrent inflammatory digit swelling.
References
Barbui T, Thiele J, Passamonti F, Tefferi A, Vannucchi AM, Barosi G. The classification of myeloproliferative neoplasms: rationale, historical background and future perspectives with focus on unclassifiable cases. Leukemia. 2021;35(2):384-402.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405.
Spivak JL. Polycythemia vera and other myeloproliferative neoplasms. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Harrison's Principles of Internal Medicine. 22nd ed. New York: McGraw Hill; 2025: 818-824.
Walden P, Zimmerman C, Hummel N, Lavu A. Estimating incidence and prevalence of polycythemia vera and associated eligibility for cytoreductive therapies in major US health plans. Blood. 2025;146(Suppl 1):8202.
Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14-22.
Siegel FP, Tauscher J, Petrides PE. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. Am J Hematol. 2013;88(8):665-9.
Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401-8.
Pelechas E, Karagianni PG, Kaltsonoudis E. The clinical significance and therapeutic management of dactylitis and enthesitis in psoriatic arthritis. Mediterr J Rheumatol. 2026;37(Suppl 1):58-67.
Anjaneyan G, Saleh HM, Kaliyadan F. Blistering distal dactylitis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2026.
Fox S, Griffin L, Robinson Harris D. Polycythemia vera: rapid evidence review. Am Fam Physician. 2021;103(11):680-7.
Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-35.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Prashanth Gopathi, Alekya Katti, Praveen Kumar Jangapalli

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.